세계의 인간 1대 세포 배양 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Human Primary Cell Culture Market Size, Share & Trends Analysis Report By Product (Primary Cells, Primary Cell Culture Media, Reagents & Supplements), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,374,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,782,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,597,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

인간 1대 세포 배양 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 인간 1대 세포 배양 시장은 2030년까지 71억 5,000만 달러에 이르며, 2025-2030년의 CAGR은 11.05%를 나타낼 것으로 예측됩니다. 1차 세포 배양 시장의 성장은 단클론항체 수요 증가, 암 연구 이니셔티브 증가, 제약 회사 및 생명공학 회사의 확대, 확립된 세포주에 대한 인간 1차 세포의 이점 증가, 세포 기반 연구에 대한 정부 지원 증가 등 몇 가지 주요 요인에 기인하고 있습니다.

단클론항체는 특정 항원을 표적으로 하는 높은 특이성과 효능으로 인해 다양한 치료 용도의 중심적 존재가 되었습니다. 1차 세포는 이러한 항체의 개발과 검사에 중요한 역할을 하고 있으며 시장에서 수요를 견인하고 있습니다. 창약, 독성 검사, 질병 모델링, 맞춤형 의료를 위해 1대 세포에 크게 의존하는 제약 및 바이오테크놀러지 산업도 현저한 성장을 이루고 있습니다. 정밀의료 및 표적 요법으로의 전환은 연구 개발 활동에서 1대 세포 수요를 증폭시켜 현대 의료 솔루션의 추진에 필수적입니다.

시장을 추진하고 있는 또 다른 중요한 요인은 감염을 연구하기 위한 보다 효과적인 모델에 대한 수요 증가입니다. COVID-19의 대유행은 백신 후보, 항바이러스제 및 기타 치료법을 검사하기 위한 정확한 모델의 필요성에 대한 인식을 높여줍니다. 인간 1대 세포 배양은 HIV, 간염, 인플루엔자와 같은 질병에 대한 새로운 백신과 치료법 개발에 필수적인 인간 조직의 반응을 충실히 모방하기 때문에 바이러스 감염 연구에 특히 적합합니다. 또한 면역세포의 거동을 재현할 수 있기 때문에 면역반응이나 숙주와 병원체의 상호작용을 이해하는데 있어서 필수적입니다.

1차 세포는 세포주보다 생물학적으로 더 적합한 연구 모델을 제공하는 반면, 높은 비용은 입수를 제한할 수 있습니다. 인간 1대 세포를 얻기 위해서는 전문 바이오 리포지토리 및 상업 벤더로부터의 정보가 필요하며, 이러한 세포는 확립된 세포주보다 상당히 비싸질 수 있습니다.

인간 1대 세포 배양 시장 보고서 하이라이트

• 제품별로는 1대 세포 부문이 2024년에 가장 큰 시장 점유율을 차지했습니다. 개인화된 의료에 대한 수요 증가, 3D 배양, 장기 온칩 플랫폼, 마이크로플루이딕스 시스템 등의 기술 진보, 창약 및 독성 검사에 대한 주목 증가가 이 부문의 성장을 이끌고 있습니다.
• 용도별로는 치료 개발 부문이 2024년 점유율로 시장을 독점했습니다. 1대 세포는 생물학적 제제, 단클론항체 및 백신의 제조에 필수적입니다. 또한, 유행학은 바이러스학에서 세포 배양의 중요한 역할을 입증하고 지속적인 투자를 촉진했습니다.
• 최종 용도별로는 제약 및 바이오테크놀러지 기업이 2024년 시장을 독점했습니다. 제약 및 바이오의약품산업은 창약, 개발, 제조를 위한 세포기반 모델의 채용 확대에 의해 시장의 대폭적인 성장을 목격하고 있습니다.
• 북미는 2024년 41.12% 시장 점유율을 차지했습니다. 북미의 인간 1대 세포 배양 산업은 몇 가지 중요한 요인에 의해 현저한 성장을 이루고 있습니다. 주요 요인은 암, 당뇨병, 심혈관 장애 등의 만성 질환의 유병률 증가이며, 이것이 창약 개발에 1대 세포 배양을 이용하는 연구 활동의 급증으로 이어지고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/보조시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 산업 분석도구
  • Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 인간 1대 세포 배양 시장 : 제품 비즈니스 분석

• 제품 부문 대시보드
• 세계의 인간 1대 세포 배양 시장의 제품 변동 분석
• 세계의 인간 1대 세포 배양 시장 규모와 동향 분석, 제품별, 2018-2030년
• 1대 세포
• 1대 세포 배양 배지
• 시약과 보충제

제5장 1대 세포 배양 시장 : 용도 비즈니스 분석

• 용도 부문 대시보드
• 세계의 인간 1대 세포 배양 시장의 용도 변동 분석
• 세계의 인간 1대 세포 배양 시장 규모와 동향 분석, 용도별, 2018-2030년
• 창약
• 치료법의 개발
• 재생 의료
• 기타

제6장 1대 세포 배양 시장 : 최종 용도 비즈니스 분석

• 최종 용도 부문 대시보드
• 세계의 인간 1대 세포 배양 시장의 최종 용도 변동 분석
• 세계의 인간 1대 세포 배양 시장 규모와 동향 분석, 최종 용도별, 2018-2030년
• 제약·바이오테크놀러지 기업
• CMO와 CRO
• 학술연구기관

제7장 1대 세포 배양 시장 : 제품, 용도, 최종 용도에 따른 지역별, 추정·동향 분석

• 지역 대시보드
• 시장 규모와 예측과 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 참가 기업
• 전략 매핑
• 기업시장 포지셔닝 분석, 2024년
• 참가 기업 개요
  • Thermo Fisher Scientific Inc.
  • STEMCELL Technologies
  • Merck KGaA
  • Lonza
  • Cell Biologics, Inc.
  • PromoCell GMBH
  • ZenBio
  • AllCells
  • American Type Culture Collection
  • Axol Biosciences Ltd.

JHS

영문 목차

영문목차

Human Primary Cell Culture Market Growth & Trends:

The global human primary cell culture market is anticipated to reach USD 7.15 billion by 2030 and grow at a CAGR of 11.05% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the primary cell culture market can be attributed to several key factors including the increasing demand for monoclonal antibodies, a rise in cancer research initiatives, the expanding number of pharmaceutical and biotechnology companies, the growing advantages of primary human cells over established cell lines, and increased government support for cell-based research.

Monoclonal antibodies have become central to various therapeutic applications due to their high specificity and effectiveness in targeting specific antigens. Primary cells play a critical role in developing and testing these antibodies, driving their demand in the market. The pharmaceutical and biotechnology industries, which rely heavily on primary cells for drug discovery, toxicity testing, disease modeling, and personalized medicine, are also experiencing significant growth. The shift toward precision medicine and targeted therapies has amplified the demand for primary cells in research and development activities, making them indispensable in advancing modern healthcare solutions.

Another significant factor propelling the market is the increasing demand for more effective models to study infectious diseases. The COVID-19 pandemic has heightened awareness around the need for accurate models to test vaccine candidates, antiviral drugs, and other therapeutic solutions. Human primary cell cultures are particularly suited for studying viral infections, as they closely mimic human tissue responses, which is critical in developing new vaccines and treatments for diseases like HIV, hepatitis, and influenza. Additionally, their ability to replicate the behavior of immune cells makes them essential in understanding immune responses and host-pathogen interactions.

While primary cells offer a more biologically relevant model for research than cell lines, their high cost can limit their accessibility. Procuring human primary cells often involves sourcing from specialized biorepositories or commercial vendors, and these cells can be considerably more expensive than established cell lines.

Human Primary Cell Culture Market Report Highlights:

• Based on product, the primary cells segment held the largest market share in 2024. The rising demand for personalized medicine, technological advancements in 3D culture, organ-on-chip platforms, and microfluidic systems, and the rising focus on drug discovery and toxicology testing drive the segment's growth.
• Based on application, the therapy development segment dominated the market with a share in 2024. Primary cells are essential for producing biologics, monoclonal antibodies, and vaccines. Moreover, the pandemic demonstrated the critical role of cell culture in virology, driving sustained investment.
• Based on end use, the pharmaceutical & biotechnology companies segment dominated the market in 2024. The pharmaceutical and biopharmaceutical industries are witnessing substantial growth in the market, driven by the growing adoption of cell-based models for drug discovery, development, and manufacturing.
• The North American region dominated the market share of 41.12% in 2024. North America's human primary cell culture industry is experiencing significant growth, driven by several key factors. A major contributor is the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders, which has led to a surge in research activities utilizing primary cell cultures for drug discovery and development.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Type Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of chronic and infectious diseases
    • 3.2.1.2. Growing focus on personalized medicine
    • 3.2.1.3. Technological innovations in 3D cell culture
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of primary cells
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Human Primary Cell Culture Market: Product Business Analysis

• 4.1. Product Segment Dashboard
• 4.2. Global Human Primary Cell Culture Market Product Movement Analysis
• 4.3. Global Human primary cell culture market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Primary Cells
  • 4.4.1. Global Primary Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Hematopoietic Cells
    • 4.4.2.1. Hematopoietic cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Skin Cells
    • 4.4.3.1. Skin cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Hepatocytes
    • 4.4.4.1. Hepatocytes market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Gastrointestinal Cells
    • 4.4.5.1. Gastrointestinal cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Lung Cells
    • 4.4.6.1. Lung cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.7. Renal Cells
    • 4.4.7.1. Renal cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.8. Heart Cells
    • 4.4.8.1. Heart cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.9. Skeletal and Muscle Cells
    • 4.4.9.1. Skeletal and muscle cells market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.10. Other Primary Cells
    • 4.4.10.1. Other primary cells market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Primary Cell Culture Media
  • 4.5.1. Global Primary Cell Culture Media Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Serum-free Media
    • 4.5.2.1. Global Serum-free Media Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Serum-containing Media
    • 4.5.3.1. Global Serum-contaning Media Market and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Other Media
    • 4.5.4.1. Global Other Media Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Reagents and Supplements
  • 4.6.1. Global Reagents and Supplements Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.2. Attachment Solutions
    • 4.6.2.1. Global Attachment Solutions Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.3. Buffers and Salts
    • 4.6.3.1. Global Buffers and Salts Market and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.4. Sera
    • 4.6.4.1. Global Sera Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.5. Growth Factors and Cytokines
    • 4.6.5.1. Global Growth Factors and Cytokines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.6. Others
    • 4.6.6.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Primary Cell Culture Market: Application Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Human Primary Cell Culture Market Application, Movement Analysis
• 5.3. Global Human primary cell culture market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Drug Discovery
  • 5.4.1. Global Drug Discovery Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Therapy Development
  • 5.5.1. Global Therapy Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Regenerative Medicine
  • 5.6.1. Global Regenerative Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Other Applications
  • 5.7.1. Global Other Applications Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Primary Cell Culture Market: End Use Business Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Global Human Primary Cell Culture Market End Use Movement Analysis
• 6.3. Global Human primary cell culture market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Global Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. CMOs & CROs
  • 6.5.1. Global CMOs & CROs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Academic Research Institutes
  • 6.6.1. Global Academic Research Institutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Primary Cell Culture Market: Regional Estimates & Trend Analysis by Product, Application, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. North America Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Australia Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Thailand Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. South Korea Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait Human Primary Cell Culture Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Participant's Overview
  • 8.4.1. Thermo Fisher Scientific Inc.
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. STEMCELL Technologies
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Merck KGaA
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Lonza
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Cell Biologics, Inc.
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. PromoCell GMBH
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. ZenBio
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. AllCells
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. American Type Culture Collection
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Axol Biosciences Ltd.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives

관련자료